CervoMed Inc. financial data

Symbol
CRVO on Nasdaq
Industry
Pharmaceutical Preparations
Location
20 Park Plaza, Suite 424, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Diffusion Pharmaceuticals Inc. (to 8/14/2023), RestorGenex Corp (to 1/14/2016), Stratus Media Group, Inc (to 3/7/2014), FERIS INTERNATIONAL, INC. (to 7/16/2008), TITAN MOTORCYCLE CO OF AMERICA INC (to 2/22/2008)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.19K % -25.8%
Debt-to-equity 10.8 %
Return On Equity 130 % +2223%
Return On Assets -39.8 % -159%
Operating Margin -134 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.25M shares +45.5%
Common Stock, Shares, Outstanding 8.25M shares +45.5%
Entity Public Float 6.8M USD
Common Stock, Value, Issued 8.25K USD +45.5%
Weighted Average Number of Shares Outstanding, Basic 8.7M shares +163%
Weighted Average Number of Shares Outstanding, Diluted 8.7M shares +131%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 10.1M USD +27.1%
Research and Development Expense 14.6M USD +609%
General and Administrative Expense 8.97M USD +426%
Operating Income (Loss) -13.5M USD -1602%
Nonoperating Income (Expense) 1.52M USD -86.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.8M USD +77.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -11.9M USD -400%
Earnings Per Share, Basic 1.08 USD/shares -185%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.74M USD -25.7%
Marketable Securities, Current 38.9M USD
Other Assets, Current 74.3K USD -48.2%
Assets, Current 48.8M USD +312%
Other Assets, Noncurrent 73.9K USD -62%
Assets 48.9M USD +306%
Accounts Payable, Current 1.08M USD +103%
Employee-related Liabilities, Current 740K USD +50.1%
Liabilities, Current 2.27M USD -17.4%
Liabilities 3.25M USD +31.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 123K USD
Retained Earnings (Accumulated Deficit) -64M USD -22.9%
Stockholders' Equity Attributable to Parent 45.6M USD +377%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.34M USD
Liabilities and Equity 48.9M USD +306%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.42M USD +3.93%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 9.5M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 8.25M shares +45.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.42M USD +3.93%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.74M USD -25.7%
Deferred Tax Assets, Valuation Allowance 24.5M USD +18.1%
Deferred Tax Assets, Gross 14.3M USD +14.4%
Depreciation 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.61M USD -314%
Deferred Tax Assets, Operating Loss Carryforwards 10.5M USD -4.39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 5K USD -64.3%
Additional Paid in Capital 110M USD +77.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 14.1M USD +13%
Share-based Payment Arrangement, Expense 1.23M USD +148%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares